INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 12, 2018	Aug. 20, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Naltrexone Implant Formulation [Member] \| Australia from Trinity Compound Solutions [Member]
Cash paid for acquisition		$ 10,000
Aggregate purchase price, Shares		20,000
Aggregate purchase price, value		$ 236,000
Patent acquired	$ 15,200
Patents [Member]
Amortization expense			$ 295	$ 292
Estimated useful lives	13 years
Accumulated amortization			2,931
Intellectual Property [Member]
Amortization expense			$ 13,795	$ 11,790	$ 47,160	$ 11,990
Estimated useful lives			5 years
Accumulated amortization			$ 70,940